G. Moriceau

发表

MDM4 is a key therapeutic target in cutaneous melanoma

Hubing Shi, A. Jochemsen, J. Marine, 2012, Nature Medicine.

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.

J. Larkin, J. Sosman, A. Ribas, 2015, Cancer cell.

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

Antoni Ribas, Kimberly B. Dahlman, Hubing Shi, 2015, Cell.

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

Tom Misteli, Mark C. Kelley, Neal Rosen, 2011, Nature.

Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process.

G. Moriceau, C. Riganti, M. Denis, 2010, Cancer research.

JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma

T. Graeber, A. Ribas, Hubing Shi, 2016, Cell Discovery.

Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors.

J. Sosman, R. Halaban, A. Ribas, 2012, Cancer discovery.

mTOR inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone tumours.

G. Moriceau, D. Heymann, B. Ory, 2007, Current medicinal chemistry.

whole-exome sequencing identifies

J. Sosman, A. Ribas, R. Scolyer, 2016 .

Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment.

G. Moriceau, F. Redini, V. Trichet, 2010, Biochimica et biophysica acta.

Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy.

Zhentao Yang, A. Ribas, D. Solit, 2021, Cancer cell.

SPRED1 deletion confers resistance to MAPK inhibition in melanoma

L. Zon, R. Lo, G. Moriceau, 2020, The Journal of experimental medicine.

Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance

S. Nelson, J. Sosman, A. Ribas, 2012, Nature Communications.

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.

Antoni Ribas, Hubing Shi, Richard A Scolyer, 2014, Cancer discovery.

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

Antoni Ribas, Hubing Shi, Mark C Kelley, 2014, Cancer discovery.

Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells

G. Moriceau, D. Heymann, B. Ory, 2008, Journal of cellular and molecular medicine.

Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy

Nathan L. Avaritt, Charity L. Washam, Zhentao Yang, 2022, bioRxiv.

Vemurafenib resistance reprograms melanoma cells towards glutamine dependence

R. Lo, G. Moriceau, Ying Yang, 2015, Journal of Translational Medicine.

Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Anti-Tumor T-cell Immunity.

Zhentao Yang, A. Ribas, P. Scumpia, 2020, Cancer discovery.

Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.

Robert Damoiseaux, Antoni Ribas, Mark C Kelley, 2017, Cancer discovery.

Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma.

N. Sharpless, R. Damoiseaux, R. Lo, 2018, Cancer discovery.

Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models

Frederic Blanchard, G. Moriceau, D. Heymann, 2014, PloS one.

Enhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance

Zhentao Yang, J. Wohlschlegel, R. Lo, 2022, Cancer discovery.

Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma

Zhentao Yang, A. Ribas, R. Lo, 2023, Cancer discovery.

Vemurafenib resistance reprograms melanoma cells towards glutamine dependence

R. Lo, G. Moriceau, Jun Wu, 2015, Journal of Translational Medicine.

Multi-organ landscape of therapy-resistant melanoma

Zhentao Yang, P. Scumpia, Douglas B. Johnson, 2023, Nature Medicine.

High-Speed Live-Cell Interferometry: A New Method for Quantifying Tumor Drug Resistance and Heterogeneity.

Jason Reed, Daniel Guest, Kevin A Leslie, 2018, Analytical chemistry.

Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth

G. Moriceau, D. Heymann, F. Redini, 2012, Cancer.

Plasticity of extrachromosomal and intrachromosomal BRAF amplifications in overcoming targeted therapy dosage challenges.

V. Bafna, T. Graeber, P. N. Rao, 2021, Cancer discovery.

Therapeutic approach of primary bone tumours by bisphosphonates.

G. Moriceau, F. Verrecchia, D. Heymann, 2010, Current pharmaceutical design.

Pharmacological blocking of the osteoclastic biocorrosion of surgical stainless steel in vitro.

A. Little, G. Moriceau, D. Heymann, 2013, Journal of biomedical materials research. Part A.